<DOC>
	<DOC>NCT00721409</DOC>
	<brief_summary>The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer</brief_summary>
	<brief_title>Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inoperable estrogen receptor positive and HER2 negative breast cancer. Postmenopausal status. Tumor tissue (archived acceptable) available for biomarker studies. For Phase 2 Part 2 CCND1 amplification and/or loss of p16 as determined by the central laboratory. Acceptable bone marrow, liver and kidney function. Prior or concomitant treatment for advanced breast cancer. Other major cancer in the past 3 years. Important cardiovascular events in the past 6 months.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hormone-receptor positive advanced breast cancer</keyword>
</DOC>